A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes

To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the haemoglobin level and transfusion requirement in low‐risk myelodysplastic syndromes (MDS), 87 patients were enrolled in a randomized double‐blind placebo‐controlled study. 44 patients were assigned to epoetin α (150 U/kg/d s....

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1998-12, Vol.103 (4), p.1070-1074
Main Authors: Ferrini, P R, Grossi, A, Vannucchi, A M, Barosi, G, Guarnone, R, Piva, N, Musto, P, Balleari, E
Format: Article
Language:English
Subjects:
Adult
Aged
anaemia
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Double-Blind Method
erythropoietin
Erythropoietin - therapeutic use
Female
Hematology
Humans
Male
Medical sciences
Middle Aged
myelodysplastic syndromes
Myelodysplastic Syndromes - therapy
Pharmacology. Drug treatments
Recombinant Proteins
Risk Factors
transferrin receptor
transfusion
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effect of recombinant human erythropoietin (rHuEpo) on the haemoglobin level and transfusion requirement in low‐risk myelodysplastic syndromes (MDS), 87 patients were enrolled in a randomized double‐blind placebo‐controlled study. 44 patients were assigned to epoetin α (150 U/kg/d s.c. for 8 weeks) and 43 to placebo arms. MDS types were homogenous in both groups: refractory anaemia (RA) 47.7–48.8%, refractory anaemia with ringed sideroblasts (RAS) 20.5–25.6%, refractory anaemia with excess of blasts (RAEB) (blasts  200 mU/l predicted for a non‐response. At week 4 sTfR levels were increased > 50% in responders (P = 0.013), whereas an increase
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1998.01085.x